At least 10 companies reduced their workforces during the third quarter, compared to at least 15 in the same period last year. All cash and operating loss figures in $M. (A) 12-month operating loss at June 30; (B) Six-month net loss at June 30

Date

Company

Staff cuts

Cash

Yrs cash pre-cut

Cash date

6-mo op loss ended 6/30

7/8/13

Evotec AG (Xetra:EVT)

Reduce by 120

$113.2

9.93

6/30/13

$5.7

Cuts from closure of Evotec India Pvt. Ltd. in Thane, India, as Evotec shifted its chemistry operations to its facility in Abingdon, U.K. Evotec cited a need to "operate closer to the principal R&D laboratories of our major customers." Evotec had 661 employees at June 30. It anticipates hiring due to growth at other sites. Cash includes €30.1M ($40.2M) raised in an August private placement.

8/7/13

Array BioPharma Inc. (NASDAQ:ARRY)

20% to ~200

$108.7

2.75

6/30/13

$39.5 (A)

Cuts primarily from drug discovery. By year end, Array expects to make decisions regarding pivotal trial plans for its two clinical cancer programs: ARRY-520, a kinesin spindle protein (KSP; Eg5; TRIP5) inhibitor; and ARRY-614, an inhibitor of P38 mitogen-activated protein (MAP) kinase and tyrosine kinase receptor 2 (Tie2). The company expects to save over $10M annually.